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by David P. Houchens,* Artemio A. Ovejera*t
and Richard W. Niemeiert
The effect ofethylene glycol monomethyl ether(EGME) and ethylene glycol monoethyl ether (EGEE) on
cell-mediated immunity wasevaluated by an allograft rejection assay. Allogeneic B6C3F1 (C57BL/6 x C3H)
mice were given oral doses of 600, 1200, or 2400 mg/kg/administration of EGEE or 300, 600, 1200
mg/kg/administration of EGME on days -12 through -8 or cyclophosphamide (Cy) at 180 mg/kg by the IP
route on day -1. Untreated controls were given oral doses ofwater on days -12 through -8 and -5 through -1.
Onday 0, the mice were challenged with 1 x 102, 3 x 103, and 1 x 105 or 3 x 106 L1210 cells by the IP route.
SyngeneicCD2F, (Balb/c x DBA/2) mice werechallenged with 1 x 105L1210 cells onday 0 andweretreated
on days 1 to 5 and 8 to 12 with the same dosages of EGME and EGEE used for the B6C3F1 mice.
Water-treated syngeneic mice died with a median survival time (MST) of 8.0 days. There was no effect on
the MST of syngeneic mice treated with either EGME or EGEE, indicating no direct antitumor effect of
the compounds. All allogeneic mice receiving either water or Cy and challenged with 3 x 106 tumor cells,
died with ascites. However, when mice were treated with EGME or EGEE and challenged with 3 x 106
tumor cells, no more than one animal per group died. This would indicate that there was a prophylactic
action ofthe compounds orthat the immune system was stimulated. Blood smears ofallogeneic mice were
made fordifferential counts the last day ofdrugdosing, theday ofdeath where possible, and on survivors at
day 43 post-tumor implantation. Differential counts showed evidence of monocytosis, considered to be
indicative of monocytic leukemia, in those mice not surviving until the day of sacrifice. All surviving
allogeneic mice were sacrificed and autopsied on day 43. Of those receiving EGEE, 7% had cholecystitis
while 58% of those receiving EGME had cholecystitis.
Introduction
In recent years, routine methods, based primarily on
animal death and/or histopathological changes, have
evolved to assess the toxicity and/or carcinogenicity of
environmental pollutants. These approaches have aided
in the identification of certain highly toxic environmen-
tal contaminants with acute effects (1). The develop-
ment of assays and/or batteries of techniques to deter-
mine the effects of these agents on more subtle cell
functions has not evolved as rapidly, and indeed in
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many instances could proceed only after assays were
developed to determine the mechanism(s) of cellular
functions, differentiation, and interactions.
Attempts to apply assays of immune function to
assess the effects of selected environmental pollutants
on this key biological system have demonstrated the
immunosuppressive effectsofheavymetals(2), polychlo-
rinated biphenyls (3), pesticides (4), fossil fuel combus-
tion products, polycyclic aromatic hydrocarbons, to
mention a few, and in selected studies the mechanism(s)
of these effects have been further clarified (1). These
types ofstudies coupled with the fact that accurate and
sensitive assays of immune function have been (and
continue to be) developed clearly indicate that immuno-
toxicology can and should be further developed and
applied.
A variety oftoxicological effects have been observed
with ethylene glycol monomethyl ether (EGME) and
ethylene glycol monoethyl ether (EGEE) including
testicular atrophy (5), adverse reproductive effectsHOUCHENS, OVEJERA AND NIEMEIER
(6,7), leukopenia (8), and thymic atrophy (9). Although
no mechanistic explanations have been suggested as a
common thread to explain these diverse observations, a
simplistic hypothesis is that there may be direct
cytotoxic effect on somerapidlygrowingtissues. Consid-
ering the contention of Trosko et al. (10) that interrup-
tion of intercellular communication may play a similar
role in teratogenesis as well as tumor promotion and
that various glycol ethers have been demonstrated to
block gap junction-mediated intercellular communica-
tion (11), the glycol ethers were judged to be likely
candidates for tumor promoting effects. In addition the
observations of thymic atrophy in mice and rats also
suggested the possibility of increased risk of tumor
development through a decrease in thymus dependent
cellular immunity. We chose to assess the effects of
these chemicals on the immune system using an
allogeneic tumor challenge model (12). In this model,
mice which are allogeneic in relation to the leukemic cell
tumor used will not die when challenged unless they
have been immunosuppressed, while in syngeneic mice
the tumor will grow and kill the animals unless there is
a direct cytotoxic effect as a result of chemical treat-
ment on the tumor cells.
Materials and Methods
The test compounds, ethylene glycol monoethyl ether
(CAS No. 110-80-5) and ethylene glycol monomethyl
ether (CAS No. 109-86-4) were purchased from Aldrich
(lot Nos. 0914EH and 3623ME, respectively). Commer-
cially available cyclophosphamide (Mead Johnson) was
used as a positive control, and distilled water was used
as the negative control compound and for the dilution
vehicle.
The mouse lymphoid leukemia L1210 was utilized in
this study. Obtained originally from the National Can-
cer Institute (NCI), this ascitic tumor is propagated
serially by intraperitoneal (IP) implantation in DBA/2
inbred mice (13).
Female hybrid mice, B6C3F1 (C57BL/6 female x
C3H male) and CD2F1 (BALB/c female x DBA/2 male)
were purchased from the Animal Genetics and Produc-
tion Branch, NCI. The mice were 5 to 6 weeks old and
weighed 17 to 21 g. The mice were maintained in
conformity with the standard guidelines (14). They
were housed in plastic cages (four to five mice per cage)
with hardwood chip bedding and provided with dry
pelleted mouse feed and water ad libitum. All mice
were quarantined for 1 week prior to randomization.
The mice were regularly inspected for gross signs of
pathogenic conditions and injury.
The allogeneic mice were randomized four to a cage
after the quarantine period. The cages were further
randomized prior to assigning to a treatment group.
Each treatment group consisted of two cages or a total
of six to eight animals. Each animal in a cage was
ear-marked for individual identification. The syngeneic
mice were randomized immediately before tumor
challenge.
L1210 ascitic fluid was harvested aseptically from
healthy donor mice and placed in a sterile glass con-
tainer on ice. A cell count was made using a
hemocytometer, and the stock fluid was diluted in
Hank's balanced salt solution to the desired cell
concentration. The number ofcellsimplanted intraperi-
toneally (3 x 106, 1 x 105, 3 x 10 , or 1 x 10 per
mouse) was contained in 0.2 mL cell suspension.
Group body weights were taken once a week during
the experimental period. Survival, general health
conditions, and other clinical observations were re-
corded daily. Necropsies were performed to record
the presence of leukemic ascites, splenomegaly, and
hepatomegaly. Smears were made from retro-orbital
sinus blood from each animal on the last day of dosing
and on the day of death (or at 43 days post-tumor
implantation for the allogeneic mice.) These smears
were stained with Giemsa and differential cell counts
were made.
The chemicals were prepared in appropriate concen-
trations and were administered to mice perorally in a
volume of 0.01 mL/g body weight. The allogeneic
B6C3F1 mice were treated daily from day -12 to day -8
and from day -5 to day -1. Day 0 was the tumor
implantation day for both strains of mice. Cyclophos-
phamide at adose of180 mg/kg was injected intraperito-
neally on day -1. The syngeneic CD2F1 mice were
treated daily on days 1 to 5 and days 8 to 12. There was
no cyclophosphamide-treated group in the syngeneic
mice. The negative control group for each strain was
Table 1. Effect of EGEE or EGME on L1210 leukemia in syngeneic mice.
Dose, Avg. body weight change, Death range, MST,
Treatmenta mglkg/adm g days daysb
EGEE 2400 1.7 8 8
1200 1.7 8-9 8
600 5.7 8 8
EGME 1200 2.3 9-10 9.5
600 1.9 9-10 9
300 1.5 9 9
Water 4.7 8-9 8
aChemicals and water were administered on days 1-5 and 8-12 (or until the animals died) after a tumor challenge of 1 x 100 L1210 leukemia
cells. Eight animals per group.
bMedian survival time.
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Table 2. Effects of EGME on L1210 leukemia in allogeneic mice.
Treatmenta
EGME
Dose,
mg/kg/adm
1200
600
300
1200
600
300
1200
600
300
1200
600
300
Cyclophdsphamide
Water
180
180
180
180
L1210 tumor
inoculum
3 x 106
3 x 106
3 x 106
1 x 100
1 x 10°
1 x 105
3 x 103
3 x 103
3 x 103
1 x 102
1 x 102
1 x 102
3 x 106
1 x 100
3 x 103
1 x 102
3 x 106
1 x 10°
3 x 103
-i - tn2
Avg. body weight
change, g
6.6
7.1
6.8
6.3
5.9
7.1
6.9
6.5
6.0
5.9
6.4
6.0
6.3
6.3
6.2
5.2
5.0
MST,
days
> 43
> 43
> 43
> 43
> 43
> 43
> 43
> 43
> 43
> 43
> 43
> 43
7
> 43
> 43
> 43
Survivors/
total
7/7
7/8
7/8
5/6
6/8
7/7
7/7
7/7
7/7
7/7
6/6
7/7
0/8
8/8
8/8
8/8
9
> 43
> 43
- AQ
0/7
8/8
6/6
/1( I X lU 1.Z -> 46 U/
IEGME and waterwere administered by gavage on days -12 through -8 and -5 through -1 before challenge with L1210 cells. Cyclophosphamide
was administered 1 day prior to tumor challenge.
Table 3. Effects of EGEE on L1210 leukemia in allogeneic mice.
Dose, L1210 tumor Avg. body weight MST, Survivors/
Treatmenta mg/kg/adm inoculum change, g days total
EGEE 2400 3 x 106 6.7 > 43 5/6
1200 3 x 106 6.7 > 43 5/6
600 3 x 106 7.0 > 43 7/8
2400 1 x 10° 12.5 > 43 5/6
1200 1 x 10 8.8 > 43 4/5
600 1 x 105 6.1 > 43 6/7
2400 3 x 103 7.3 > 43 7/7
1200 3 x 103 7.3 > 43 7/7
600 3 x 103 6.3 > 43 8/8
1200 1 x 102 6.0 > 43 7/7
600 1 x 102 7.0 > 43 7/7
Cyclophosphamide 180 3 x 106 7 0/8
180 1 x 100 6.3 > 43 8/8
180 3 x 103 6.2 > 43 8/8
180 1 x 102 6.2 > 43 8/8
Water 3 x 106 9 0/7
1 x 10° 5.2 > 43 8/8
3 x 103 5.0 > 43 6/6
lx 102 6.2 >43 6/6
aEGEE and water were administered by gavage on days -12 through -8 and -5 through -1 before challenge with L1210 cells. Cyclophosphamide
was administered 1 day prior to tumor challenge.
given distilled water on the days corresponding to the
chemical treatment days.
Results
The survival and weight results for the experiment
are presented in Table 1 for the syngeneic mice. The
challenge with 1 x 105 L1210cells inwater-treated mice
produced deaths, with a median survival time (MST) of
8.0 days. This is the acceptable range (8-11 days) for
the L1210 tumor at this challenge level. There was no
pronounced effect oftreatment with either drug at any
dose level on the prolongation of life. The groups
treated with the EGME did survive slightlylongerthan
the EGEE-treated group and the water-treated
controls. These differences in survival were small and
are not considered biologically significant in this tumor
model by NCI standards. However, pairwise compari-
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sons (two-sample t-test) showed that the differences are
statistically significant (p < 0.0001). No toxicity was
seen as assessed by body weight change with either
chemical at any dose.
Necropsy of syngeneic mice showed hemorrhagic
ascites and splenomegaly. Liver, lungs, and kidneys
were normal in gross appearance for most animals.
Groups which received the top two doses ofthe EGME
compound, each had one mouse with no visible ascites
and two each with a small quantity of ascites.
With the allogeneic mice, all animals died at the 3 x
106 challenge level in the cyclophosphamide-treated
group and the water-treated controls (Tables 2 and 3).
These groups differed significantly (p < 0.0001) from
the 3 x 106 challenge groups treatedwith EGME (Table
2) or with the EGEE (Table 3) where no more than one
animal died in each group. No mice challenged with 1 x
Table 4. Incidence ofmonocytic leukemiabydifferential cell count
in syngeneic mice treated with EGME or EGEE.
Differential count'
Treatment Dose,
groupa mg/kg No.b HM L
EGME
1200 7 0 7
600 7 0 6
300 6 0 6
EGEE
2400 8 0 8
1200 7 1 5
600 6 0 6
Water 7 0 6
'All mice treated with 1 x 105 cells tumor challenge. Where there
were less than 8 initial mice per group, the animals died before the
blood sample could be obtained.
bNo. = initial number of mice.
CCriteria: normal = 0-8% monocytes; high = 9-14% monocytes;
monocytosis indicative of monocytic leukemia : 15% monocytes.
HM = high monocyte count. L = monocytosis presumed indicative
of monocytic leukemia.
105, 3 x 103, or 1 x 102 L1210 cells died in the water
treatment groups. Likewise, no mice died at those
challenge levels in the cyclophosphamide-pretreated
mice. However, the mice which were given cyclophos-
phamide and challenged wtih 1 x 105 cells, developed
ascites as noted by abdominal distention. This devel-
oped at day 7 and was noted until approximately day 14,
when all of the ascites was resorbed and the mice
continued to live until termination on day 43. Necropsy
of these animals showed no signs of tumor.
In allogeneic mice treated with EGME compound,
one animal each died at the two lower treatment doses
withthe 3 x 106 challenge levelwhile one animaldied at
the top treatment dose and two died at the second dose
at 1 x 105challenge. One animaldiedinthe groupwhich
received the 600 mg/kg dose of EGME compound and
was challenged with 3 x 103 cells. All mice that died in
these groups had either ascites, splenomegaly, and/or
hepatomegaly. With the EGEE compound, only one
death in each group at the 3 x 106 and 1 x 10 level
occurred, while no deaths occurred at any dose level
with the 3 x 103 and 1 x 102 challenge level (Table 3).
All surviving allogeneic mice were sacrificed on day 43
for necropsy and blood smears. No mice showed any
ascites and only 4 (6%) showed splenomegaly. Of the
67 mice treated with the EGEE that survived, 5 (7%)
had enlarged gallbladders, while ofthe 79 mice treated
with the EGME compound that survived, 46 (58%)
had enlarged gallbladders. No surviving animals that
received cyclophosphamide or water had enlarged gall-
bladders.
The data from the blood counts is seen in Tables 4 to
6. In general, the morphology of the 'leukemic cells"
appeared as atypical, vaculoized mononuclear cells with
characteristic red granules. Syngeneic mice died with
evidence of monocytosis which is presumed to be
indicative of monocytic leukemia (Table 4). Most of
these treated animals were sacrificed and bled on day 43
after tumor challenge. A few mice treated with EGME
Table 5. Incidence of monocytic leukemia by differential cell count in allogeneic mice treated with EGME.a
Tumor challengea
Pretumor 3 x 106 1 x 105 3 x 103 1 x 102
challenge cells/mouse cells/mouse cells/mouse cells/mouse
Treatment
group No b HMb Lb Nsb HMb Lb Db Ns HM L D Ns HM L D Ns HM L D
EGME
1200 mg/kg 26 0 1 7 0 0 - 5 0 0 1 7 0 0 - 6 0 0
600 mg/kg 30 0 2 7 0 0 1 6 1 0 2 6 0 0 1 7 0 0
300 mg/kg 29 0 0 7 0 0 1 7 0 0 - 7 0 0 - 7 1 0
Water 27 0 0 6 1 5t 1 8 0 0 - 6 0 0 - 6 0 1
CYCd 32 0 0 - - - 8 8c 0 0 _ 8 0 0 - 8 0 0 -
aCriteria: Normal = 0-8 % monocytes; high = 9-14% monocytes; monocytosis indicative of monocytic leukemia > 15% monocytes.
bNo. = initial number of mice = Ns + D; Ns = number of mice sampled; HM = High monocyte count; L = monocytosis presumed
indicative of monocytic leukemia; D = died without blood sample.
cAs noted in the text, this group developed ascites at day 7 which was noted until approximately day 14 when all ofthe ascites was resorbed
and the mice survived until sacrifice on day 43.
dCYC = cyclophosphamide (180 mg/kg).
*Significantly different from water control (p < 0.005).
tSignificantly different from pretumor challenge (p < 0.00001).
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Table 6. Incidence of monocytic leukemia by differential cell count in allogenic mice treated with EGEE.
Tumor challengea
Pretumor 3 x 106 1 x 105 3 x 103 1 x 102
Treatment challenge cells/mouse cells/mouse cells/mouse cells/mouse
group No b HMb Lb Nsb HMb Lb Db Ns HM L D Ns HM L D Ns HM L D
EGEE
2400 mg/kg 18 1 2 5 2 0* 1 5 1 0 1 6 1 1 - Not done
1200 mg/kg 25 0 1 5 0 0* 1 4 0 1 1 7 0 0 - 7 2 0
600 mg/kg 30 2 1 7 0 ot 1 6 0 0 1 8 1 0 - 7 0 0
Water 27 0 0 6 1 5$ 1 8 0 0 - 6 0 0 - 6 0 1
CYCC 32 0 0 - - - 8 8d 0 0 _ 8 0 0 - 8 0 0 -
aCriteria: normal = 0-8% monocytes; high = 9-14% monocytes; monocytosis presumed indicative ofmonocytic leukemia : 15% monocytes.
bSee Table 5.
CCYC = cyclophosphamide (180 mg/kg).
dAs noted in the text, this group developed ascites at day 7 which was noted until approximately day 14 when all ofthe ascites was resorbed
and the mice survived until sacrifice on day 43.
*Significantly different from water control (p < 0.02).
tSignificantly different from water control (p < 0.005).
*Significantly different from pretumor challenge (p < 0.00001).
**Significantly different from pretumor challenge (p < 0.05).
or EGEE (Tables 5 and 6) but not challenged with
tumors showed evidence ofmonocytosis. Since no gross
pathological observations were made at the time ofthe
first bleeding, one can only speculate on the cause. It is
reasonable to assume that penetration ofthe esophagus
or trachea may have occurred due to dosing error
resulting in an infection. However, ofthe four mice that
died in the EGEE group, two who had monocytosis at
the first bleeding died with evidence ofleukemia (one in
the 1200 and one in the 2400 mg/kg group). This also
occurred in one mouse treated with 600 mg/kg EGME.
The remaining animals with evidence ofmonocytosis at
the first bleeding had a normal blood profile at sacrifice.
Discussion
The results shown for the syngeneic mice demon-
strate that there is probably no direct antitumor
activity of the compounds against the L1210 tumor at
the doses or schedule which were evaluated. At the
same time there was no toxicity as assessed by weight
loss or early death. This could indicate that higher
dosages might be tolerated and have some direct
cytotoxic effect on the tumor.
The results for the allogeneic mice are somewhat
more complex. It is apparent that the 3 x 106 tumor
challenge level was able to overcome the allogeneic
rejection phenomenon in that all water-treated controls
died, as did the cyclophosphamide-pretreated mice. The
mice treated with cyclophosphamide and challenged
with 1 x 105 cells developed ascites, but were still able
to overcome tumor by rejection. The fact that most of
the allogeneic mice pretreated with either test com-
pound and challenged with 3 x 106 L1210 cells did not
die would seem to indicate that the compounds have
some type of prophylactic action or may in some way
actually stimulate the immune system, since the compa-
rable control mice died with this challenge.
The results are interesting in that they appear to
support the observations of overall decreases in back-
ground gross pathology of the spleen, pituitary, testes
or mammary gland in aging Fischer 344 rats adminis-
tered EGEE by oral gavage (15). The current study
suggests that EGEE and EGME may exert an antitu-
mor effect through increased immunological compe-
tence or immunomodulation.
To more accurately determine what immunologic
effects these compounds have in an allogeneic tumor
model, in comparison with the standard immunosup-
pressive compound cyclophosphamide, an experiment
withthefollowinfchallenge levels is suggested: 5 x 106,
1 x 106, 5 x 10 , 1 x 10 . This should produce groups
where the cyclophosphamide treated groups will die,
but the water-treated controls will not (1 x 106 and 5 x
105). Further, higher doses ofthe compounds that would
produce pronounced toxic effects (e.g., death, weight
loss, bone marrow toxicity), as well as additional assays
to assess immune competence, should be included.
Since these glycol ethers exhibit relatively low toxic-
ity in organ systems other than the reproductive tract,
arereadilyabsorbedbyvariousroutesofadministration,
and appear to decrease background gross pathology,
there may be enough evidence to warrant testing of
these chemicals as potential therapeutic agents.
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